Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...
DexCom (DXCM) stock has been in focus after Investor Day communications that many fund managers say improved sentiment, ...
Heald, a digital metabolic health platform, today announced that consumers who purchase a Dexcom Stelo or Abbott Lingo continuous glucose monitor (CGM) through Heald will now receive complimentary ...
Smartwatches still can’t measure blood sugar on their own, but AI-powered CGMs are changing how glucose data is tracked and ...
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue ...
DXCM's expanding CGM reach, G7 15 Day rollout and international momentum support growth, but can reimbursement and cost risks ...
Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...
My continuous glucose monitor once showed me that oatmeal spikes my blood sugar higher than ice cream does. I have worn one since January 2025, and that’s a disclosure, not an endorsement. What ...
Morning Overview on MSN
The FDA cleared the first over-the-counter glucose monitor made for children
Parents of young children with elevated blood sugar now have a new option that does not require a doctor’s prescription. The ...
AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...
On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 diabetes using insulin therapy, as well as certain non-insulin users who ...
FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, school device rules, and reimbursement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results